DXCM
US EQUITY
Health Care
Health Care Equipment
CIK: 1093557
Dexcom (DXCM) Quant Factor Diagnostic & Fair Value Model
Dexcom (Ticker: DXCM) is listed in the Health Care sector (Health Care Equipment). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$77.94
-0.49%
Latest Close (2026-10-23)
Market Cap: $29.41B
P/E Ratio: 30.4
Momentum Strength
3M / 12M
+6.23%
1M: -10.90%
12M: +10.24%
Quality (ROE)
Point-in-Time
+38.01%
Trailing Return on Equity
Technical Trend
RSI 14
30.6
SMA50: $86.83
SMA200: $74.31
Valuation Multiplier
Trailing
30.4
Premium Multiple (> 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Premium Multiple (> 30x P/E)
DXCM trades at 30.4x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 7/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1093557 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-07-30 | - | $249.10M | $794.80M | $0.64 |
| 10-Q | 2025-12-31 | 2026-07-30 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-07-30 | - | $179.80M | $486.80M | $0.45 |
| 10-Q | 2026-03-31 | 2026-04-30 | - | $199.50M | $525.60M | $0.51 |
| 10-Q | 2025-03-31 | 2026-04-30 | - | $105.40M | $183.80M | $0.27 |
| 10-K | 2025-12-31 | 2026-02-12 | - | $836.30M | $1.44B | $2.09 |
| 10-K | 2024-12-31 | 2026-02-12 | - | $576.20M | $989.50M | $1.42 |
| 10-K | 2023-12-31 | 2026-02-12 | - | $541.50M | $748.50M | $1.30 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Dexcom (DXCM) valuation multiples, momentum factors, and point-in-time filing conventions.
How should DXCM's current valuation multiple be interpreted? ↓
DXCM trades at a trailing P/E of 30.4x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are DXCM's key momentum and technical factor indicators? ↓
As of the latest close, DXCM shows a 1-month return of -10.90%, 3-month return of +6.23%, and 12-month return of +10.24%, with a 14-day RSI of 30.6. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for DXCM? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can DXCM be incorporated into systematic factor models? ↓
DXCM can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.